在精神分裂症中皮质GABAergic神经元失调是年龄依赖的
Daniel Kiss1,2, Xiaolin Zhou1,2,3, Nicole Endresz1,2,4
1Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Biological psychiatry global open science
|October 29, 2025
概括
精神分裂症 (SCZ) 涉及大脑细胞的变化,特别是胺黄油酸性 (GABAergic) 神经元. 这项研究发现,这些变化随着年龄的变化而变化,影响帕瓦尔胺 (PVALB) 和索马托斯塔丁 (SST) 细胞比例和基因表达.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学是一种遗传学.
- 精神病学是一个精神病学.
背景情况:
- 皮质GABAergic神经元的失调与精神分裂症 (SCZ) 有关.
- 目前尚不清楚SCZ是否涉及这些神经元内的改变细胞数或基因表达.
研究的目的:
- 为了研究GABAergic神经元比例和SCZ中的基因表达的年龄相关变化.
- 在SCZ中区分细胞类型比例和每细胞表达变化.
主要方法:
- 分析了来自1408名个体的14个RNA测序数据集 (SCZ病例和对照).
- 使用解卷方法来估计GABAergic细胞亚型比例从散装RNA-seq.
- 评估了细胞比例和每个细胞基因表达的SCZ和年龄相关变化.
主要成果:
- 在SCZ中,帕瓦胺 (PVALB) 和体静止素 (SST) 细胞的比例发生变化,因死亡时的年龄而异.
- 年轻的SCZ病例 (70岁以下) 减少了PVALB和SST细胞比例.
- 在较年轻的SCZ病例中观察到减少的每细胞SST和血管活性肠mRNA.
结论:
- SCZ与GABAergic神经元,特别是PVALB和SST细胞的复杂,年龄相关的变化有关.
- 年龄分层分析对于理解SCZ病理生理学至关重要.
- 在不同的SCZ患者群体中,不同的病理过程可能是GABAergic神经元变化的基础,这表明了定制治疗方法.
相关概念视频
Biological Causes of Schizophrenia
485
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
485
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
1.8K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.8K
Pharmacodynamics in Geriatric Patients: Effects of Age
183
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
183
Psychological and Sociocultural Causes of Schizophrenia
465
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
465
Schizophrenia
735
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those...
735
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K


